Signaling-specific inhibition of the CB1 receptor for cannabis use disorder

Haney, M., Vallée, M., Fabre, S. et al. Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. Nat Med 29, 1487–1499 (2023). https://doi.org/10.1038/s41591-023-02381-w 

AEF0117 significantly reduced cannabis’ positive subjective effects (primary outcome measurement, assessed by visual analog scales) by 19% (0.06 mg) and 38% (1 mg) compared to placebo (P < 0.04). AEF0117 (1 mg) also reduced cannabis self-administration (P < 0.05). In volunteers with CUD, AEF0117 was well tolerated and did not precipitate cannabis withdrawal. These data suggest that AEF0117 is a safe and potentially efficacious treatment for CUD.

Popular posts from this blog

Managing Patients Taking Xylazine-Adulterated Opioids in Emergency, Hospital, and Addiction Care Settings

Prescription Drug Misuse and Addiction: Compassionate Care for a Complex Problem

International Overdose Awareness Day, August 31